Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02074839
Recruitment Status : Active, not recruiting
First Posted : February 28, 2014
Last Update Posted : February 23, 2018
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.